ChemMedChemPub Date : 2024-11-19DOI: 10.1002/cmdc.202400525
Andrii S Myshko, Galyna P Mrug, Svitlana P Bondarenko, Bohdan A Demydchuk, Oleksandr L Kobzar, Vladyslav M Buldenko, Andriy I Vovk, Mykhaylo Frasinyuk
{"title":"Divergent Synthesis of Novel 3(5)-Aminoazole-Benzopyrone Hybrids and their Evaluation as α-Glucosidase Inhibitors.","authors":"Andrii S Myshko, Galyna P Mrug, Svitlana P Bondarenko, Bohdan A Demydchuk, Oleksandr L Kobzar, Vladyslav M Buldenko, Andriy I Vovk, Mykhaylo Frasinyuk","doi":"10.1002/cmdc.202400525","DOIUrl":"https://doi.org/10.1002/cmdc.202400525","url":null,"abstract":"<p><p>An efficient approach has been developed for the trapping in situ generated benzopyrone-based ortho-quinone methide intermediates by 3- and 5-amino pyrazoles or isoxazoles. In cases of naturally occurring phenolic Mannich bases, hybrid compounds between the azole and flavonoid, namely, coumarin, chromone, isoflavone, and aurone were synthesized in moderate to good yields. It is remarkable that depending on 3- or 5-position of the amino group, the reaction led to the formation of C-4 or 3-NH substituted azole derivatives, respectively. In vitro studies showed that some of the obtained compounds bearing 5-aminoisoxazole part exhibit inhibitory activity towards α-glucosidase with IC50 values in the micromolar range.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202400525"},"PeriodicalIF":3.6,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142666541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ChemMedChemPub Date : 2024-11-18DOI: 10.1002/cmdc.202400700
Olivier Beyens, Sam Corthaut, Anne-Marie Lambeir, Pieter Van Der Veken, Yann G-J Sterckx, Ingrid De Meester, Hans De Winter
{"title":"An interdisciplinary approach provides insights into the pronounced selectivity of compound 42 for DPP9.","authors":"Olivier Beyens, Sam Corthaut, Anne-Marie Lambeir, Pieter Van Der Veken, Yann G-J Sterckx, Ingrid De Meester, Hans De Winter","doi":"10.1002/cmdc.202400700","DOIUrl":"https://doi.org/10.1002/cmdc.202400700","url":null,"abstract":"<p><p>Dipeptidyl peptidase 8 (DPP8) and 9 (DPP9) are proteases gaining significant attention for their role in health and disease. Distinctive studies of these proteases are hampered by their close homology. Furthermore, designing selective compounds is a major challenge due to the highly conserved catalytic site. Here, we provide mechanistic insights underlying the DPP9-over-DPP8 selectivity of the semi-selective inhibitor \"Compound 42\". We performed enhanced sampling molecular dynamics simulations to investigate the binding pose of \"Compound 42\", which enabled the design of various DPP9 mutants that were characterized through a combination of biochemical (Ki determinations) and in silico approaches. Our findings show that DPP9 residue F253 is an important selectivity-determining factor. This work marks the discovery and validation of a structural feature that can be exploited for the design of DPP8 or DPP9 selective inhibitors.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202400700"},"PeriodicalIF":3.6,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142646086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Pleiotropic Nanomedicine Mitigates Splenic Hyperplasia, Ineffective Erythropoiesis, G6PDH Anomaly through Redox Buffering in Preclinical Mice Model.","authors":"Monojit Das, Susmita Mondal, Ria Ghosh, Lopamudra Roy, Anjan Kumar Das, Siddhartha Sankar Bhattacharya, Debasish Pal, Debasish Bhattacharya, Prantar Chakrabarti, Asim Kumar Mallick, Jayanta Kumar Kundu, Samir Kumar Pal","doi":"10.1002/cmdc.202400698","DOIUrl":"10.1002/cmdc.202400698","url":null,"abstract":"<p><p>Here, we present a pleiotropic nanomedicine-a smart, functionalized redox buffering nanoparticle-that may be used to treat hematological diseases, associated splenic hyperplasia, and issues related to restricted erythropoiesis. With a diameter of 5-7 nm, the spherical nanomaterial is made of manganese oxide and citrate. Here, we have produced the novel nanomaterial and, using cutting-edge electron microscopic and spectroscopic techniques, extensively assessed its redox buffering potential in vitrowith its structural integrity. Using an appropriate animal model (phenyl hydrazine, PHz, intoxicated C57BL/6J mice), we assessed the therapeutic efficacy of the redox buffering nanomedicine in the treatment of anemia and related consequences. We have further investigated the intricate molecular mechanism of the nanomedicine and its therapeutic impact, which includes increased erythropoiesis and G6PDH production, decreased inflammatory responses, mitigation of splenic hyperplasia, and synergistic intracellular redox-buffering. To the best of our knowledge, our studies would find relevance in the innovative management of anemia, decreased erythropoiesis, and splenic hyperplasia.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202400698"},"PeriodicalIF":3.6,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ChemMedChemPub Date : 2024-11-14DOI: 10.1002/cmdc.202400816
David Michael Whitehead, Christian Fischer, Emmanuelle Briard, Christopher Farady, Nadège Graveleau, Joel Karrer, Klemens Kaupmann, Guillaume Lapointe, Angela Mackay, Lisa Reichert, Michael Wright, Linjing Mu, Yves P Auberson
{"title":"[18F]NP3-627, a candidate PET imaging agent targeting the NLRP3 inflammasome in the central nervous system.","authors":"David Michael Whitehead, Christian Fischer, Emmanuelle Briard, Christopher Farady, Nadège Graveleau, Joel Karrer, Klemens Kaupmann, Guillaume Lapointe, Angela Mackay, Lisa Reichert, Michael Wright, Linjing Mu, Yves P Auberson","doi":"10.1002/cmdc.202400816","DOIUrl":"https://doi.org/10.1002/cmdc.202400816","url":null,"abstract":"<p><p>We describe the identification of a candidate positron emission tomography (PET) imaging agent for the NLRP3 protein. NLRP3 plays a critical role in the immune system and has proven a difficult target for the development of imaging agents due to its low and cell-specific expression profile. A recently described series of pyridazine-based inhibitors, with improved permeability and brain-penetration properties, was used as a starting point for the development of a suitable PET imaging agent. Optimization of affinity, non-specific binding and pharmacokinetic properties led to the identification of aminopyridazine (R)-2-(6-((1-cyclopropylpiperidin-3-yl)amino)pyridazin-3-yl)-5-fluoro-3-methylphenol (17b), which meets the preclinical profile of a successful imaging agent, and whose tritiated version demonstrated excellent specificity in a radioligand saturation binding assay, confirming its imaging potential.18F labeling led to [18F]NP3-627, the proposed PET imaging agent.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202400816"},"PeriodicalIF":3.6,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ChemMedChemPub Date : 2024-11-14DOI: 10.1002/cmdc.202400628
Mark R Petchey, Pascal Schneider, Lucy A Harwood
{"title":"Biocatalytic Amino Acid Functionalisation.","authors":"Mark R Petchey, Pascal Schneider, Lucy A Harwood","doi":"10.1002/cmdc.202400628","DOIUrl":"https://doi.org/10.1002/cmdc.202400628","url":null,"abstract":"<p><p>The success of new therapeutic modalities relies on advancements in synthetic chemistry to produce compounds for evaluation throughout the drug discovery process. The use of non-canonical amino acids (ncAAs) allows the properties of peptide drugs to be modified and optimised beyond the defined characteristics of the 20 proteogenic amino acids. Synthesis of ncAAs can be either through a bespoke chemical synthesis, or directly from the parent compound - using either traditional chemical reagents or using enzymes - to achieve the desired modification. This review will highlight recent advancements in the enzymatic functionalisation of amino acids to produce a variety of ncAAs.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202400628"},"PeriodicalIF":3.6,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ChemMedChemPub Date : 2024-11-11DOI: 10.1002/cmdc.202400727
Martin Napierkowski, Tom Schöne, Siva Sankar Murthy Bandaru, Jo Judernatz, Lukas Schulig, Louis Schmidt, Carola Schulzke, Patrick Bednarski
{"title":"Structure-Activity-Relationships of the Stability of six Pentathiepins towards Glutathione: Possible Correlations with Biological Activities.","authors":"Martin Napierkowski, Tom Schöne, Siva Sankar Murthy Bandaru, Jo Judernatz, Lukas Schulig, Louis Schmidt, Carola Schulzke, Patrick Bednarski","doi":"10.1002/cmdc.202400727","DOIUrl":"https://doi.org/10.1002/cmdc.202400727","url":null,"abstract":"<p><p>The biological properties of pentathiepins have been intensively studied in recent years. Although the proposed mechanism of action requires activation by intracellular thiols, the dependence of activity on the stability of pentathiepins towards glutathione (GSH) has not been directly investigated. Here, we determined the structure-related stability of six different pentathiepins with four different scaffolds in the presence of GSH by using reversed-phase high-performance liquid chromatography (RP-HPLC) and UV-vis spectroscopy over a wide range of GSH concentrations. We found significant differences in compound stability depending on the pentathiepin scaffold; these differences were reflected in their cytotoxic activities. However, we found no substantial differences in their inhibition of glutathione peroxidase 1 (GPx-1). While the intact pentathiepin ring is necessary for the antiproliferative activity of pentathiepins, the depletion of intracellular GSH content with dl-buthionine-(S,R)-sulfoximine (BSO) led to a significant increase in cytotoxicity of the tested substances. In view of the increased cytotoxicity following artificial GSH depletion, this calls into question the sole role of GSH in the intracellular activation mechanism.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202400727"},"PeriodicalIF":3.6,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"New Indole-based Phenylthiazolyl-2,4-dihydropyrazolones as Tubulin polymerization inhibitors: Multicomponent synthesis, cytotoxicity evaluation, and in silico studies.","authors":"Bulti Bakchi, Geetanjali Devabattula, Sarvan Maddipatla, Anuradha Singampalli, Dileep Kumar Porna, Srinivas Nanduri, Anamika Sharma, Chandraiah Godugu, Venkata Madhavi Yaddanapudi","doi":"10.1002/cmdc.202400817","DOIUrl":"https://doi.org/10.1002/cmdc.202400817","url":null,"abstract":"<p><p>A facile multicomponent synthesis of new indole-based phenylthiazolyl-dihydropyrazolone hybrids, their structural characterization, biological evaluation, and in silico investigations as anticancer agents are reported. Lead molecule 5i of the series showed potent activity against MCF-7 breast cancer cells with an IC50 of 3.92 ± 0.01 µM while showing minimal toxicity to normal human lung cells (IC50 = 69.85 ± 3.95 µM). Further studies show that the compound exhibits antiproliferative activity by inducing apoptosis in MCF-7 cancer cells. The wound healing assay indicated impaired cell migration under the concentration-dependent dosage. The lead molecule 5i also successfully inhibited the tubulin polymerase enzyme with an IC50 of 4.16 ± 0.18 µM. A flow cytometric assay indicated compound 5i induced apoptosis through G0 phase cell cycle arrest. The binding mode and interactions of the compound with the tubulin were predicted by molecular modelling and calculating binding free energies. These findings explain the current series as a new class of microtubule polymerization inhibitors with anticancer activity suitable for developing anticancer agents targeting tubulin.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202400817"},"PeriodicalIF":3.6,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Synthesis and evaluation of fluorinated piperazine-hydroxyethylamine analogues as potential antiplasmodial candidates.","authors":"Charu Upadhyay, Shreya Bhattacharya, Sumit Kumar, Kapil Vashisht, Xujie Zhang, Dominic Gagnon, Pooja Singh, Peng Zhan, Dave Richard, Brijesh Rathi, Agam Prasad Singh, Priyamvada Singh","doi":"10.1002/cmdc.202400616","DOIUrl":"https://doi.org/10.1002/cmdc.202400616","url":null,"abstract":"<p><p>In this manuscript, twenty-one novel fluorinated piperazine-hydroxyethylamine analogues were synthesized and tested against Plasmodium falciparum (Pf). Among tested compounds, two 13g and 14g exhibited promising inhibitory activity on Pf3D7 with IC50 values of 0.28 and 0.09 µM, respectively. Neither of the hits exhibited cytotoxicity on HepG2 cells up to 150 µM and Vero cells up to 20 µM. Compounds 13g and 14g were also evaluated against chloroquine-resistant PfDd2 and displayed IC50 values of 0.11 and 0.10 µM, respectively. Next, 13g and 14g were administered to the Plasmodium berghei mice model at 30mg/kg intraperitoneally for four consecutive doses, which showed 25% and 50% reduction in the parasitemia load, respectively. The efficacy of hits 13g and 14g was improved along with mean survival time when administered in combination with artesunate. On liver-stage parasites, compounds 13g and 14g showed >90% inhibition at 1µM. Compound 14g was also tested for toxicity in mice at 100 mg/kg dose, which revealed no abnormality in mice organs. Preliminary pharmacokinetic studies of compound 14g exhibited absorption and maintained a presence in the body for more than six hours.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202400616"},"PeriodicalIF":3.6,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ChemMedChemPub Date : 2023-09-01DOI: 10.1002/cmdc.202300461
Dr. Gustavo da Silva, André F. S. Luz, Denise Duarte, Dr. Diana Fontinha, Dr. Vera L. M. Silva, Dr. Filipe A. Almeida Paz, Dr. Ana M. Madureira, Dr. Sandra Sim?es, Dr. Miguel Prudêncio, Dr. Fátima Nogueira, Prof. Artur M. S. Silva, Prof. Rui Moreira
{"title":"Front Cover: Facile Access to Structurally Diverse Antimalarial Indoles Using a One-Pot A3 Coupling and Domino Cyclization Approach (ChemMedChem 17/2023)","authors":"Dr. Gustavo da Silva, André F. S. Luz, Denise Duarte, Dr. Diana Fontinha, Dr. Vera L. M. Silva, Dr. Filipe A. Almeida Paz, Dr. Ana M. Madureira, Dr. Sandra Sim?es, Dr. Miguel Prudêncio, Dr. Fátima Nogueira, Prof. Artur M. S. Silva, Prof. Rui Moreira","doi":"10.1002/cmdc.202300461","DOIUrl":"https://doi.org/10.1002/cmdc.202300461","url":null,"abstract":"<p><b>The Front Cover</b> depicts a female <i>Anopheles</i> spp. mosquito, the vector of <i>Plasmodium falciparum</i> and perhaps the most iconic image associated with the fight against malaria, which inspects the structure of a new indole scaffold with promising activity against blood-stage malaria parasites, under the moonlight (the vector has a nocturnal feeding habit, where transmission occurs). The highlighted lead compound is rising to the moon and above blood-stage parasitic forms of <i>P. falciparum</i>, in which this new scaffold revealed preferential inhibitory activity. The copyrighted <i>Anopheles</i> picture is used with the permission of Prof. Laurence J. Zwiebel. Cover design by Natália Marques Mota. More information can be found in the Research Article by Gustavo da Silva, Rui Moreira et al.<figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"18 17","pages":""},"PeriodicalIF":3.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.202300461","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"6049977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ChemMedChemPub Date : 2023-08-17DOI: 10.1002/cmdc.202300429
Μarianna Stampolaki, Anja Hoffmann, Dr. Kumar Tekwani, Kyriakos Georgiou, Dr. Christina Tzitzoglaki, Dr. Chunlong Ma, Dr. Stefan Becker, Patrick Schmerer, Kristin D?ring, Dr. Ioannis Stylianakis, Dr. Andreea L. Turcu, Prof.?Dr. Jun Wang, Prof.?Dr. Santiago Vázquez, Prof.?Dr. Loren B. Andreas, Prof.?Dr. Michaela Schmidtke, Prof.?Dr. Antonios Kolocouris
{"title":"Front Cover: A Study of the Activity of Adamantyl Amines against Mutant Influenza A M2 Channels Identified a Polycyclic Cage Amine Triple Blocker, Explored by Molecular Dynamics Simulations and Solid-State NMR (ChemMedChem 16/2023)","authors":"Μarianna Stampolaki, Anja Hoffmann, Dr. Kumar Tekwani, Kyriakos Georgiou, Dr. Christina Tzitzoglaki, Dr. Chunlong Ma, Dr. Stefan Becker, Patrick Schmerer, Kristin D?ring, Dr. Ioannis Stylianakis, Dr. Andreea L. Turcu, Prof.?Dr. Jun Wang, Prof.?Dr. Santiago Vázquez, Prof.?Dr. Loren B. Andreas, Prof.?Dr. Michaela Schmidtke, Prof.?Dr. Antonios Kolocouris","doi":"10.1002/cmdc.202300429","DOIUrl":"https://doi.org/10.1002/cmdc.202300429","url":null,"abstract":"<p><b>The Front Cover</b> illustrates the L26F variant of the M2 protein of influenza A virus which is resistant to the amantadine class of drugs. It shows the combination of two methods (MD simulations and MAS NMR) that reveal the binding of a potent inhibitor of the L26F M2 proton channel, RL208, or compound <b>61</b> in the corresponding research. The ligand RL208 is an isomer of amantadine and is described as a triple blocker of WT, L26F, V27A M2 variants. Cover design by Marianna Stampolaki and Kyriakos Georgiou; image <i>Virus Bacterium Infection</i> by PublicDomainPictures from Pixabay used in accordance with the Pixabay license. More information can be found in the Research Article by Μarianna Stampolaki, Anja Hoffmann, Loren B. Andreas, Michaela Schmidtke, Antonios Kolocouris et al.<figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"18 16","pages":""},"PeriodicalIF":3.4,"publicationDate":"2023-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.202300429","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"5695847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}